Please upgrade your browser.
The companies are taking advantage of frightened cancer patients and their loved ones, said consumer safety officer Nicole Kornspan.
Researchers at the Mayo Clinic found surgery for patients with late-stage kidney cancer may more than double their life expectancy.
Being obese, with a body mass index ( BMI) of 30 or more, increases the risk of getting kidney cancer. It causes around 25% of cases in men and 22% in women.
Kidney Cancer Association (KCA) sponsors 12th annual medical meeting in Munich, Germany
A total of 462 patients were enrolled in the ADAPT study and randomized 2:1 between combination treatment with Rocapuldencel-T and sunitinib (combination arm) vs. sunitinib monotherapy (control arm).
Do high-risk clear cell renal cancer (ccRCC) (≥pT3 or node-positive) patients receiving adjuvant sunitinib or sorafenib have improved disease-free survival, and does the dose intensity of either drug affect outcome?
Between the frontline and second-line settings, there are multiple treatment options available for patients with renal cell carcinoma (RCC), but it is critically important for oncologists to decide on an agent with a patient’s characteristics—and goals—in mind, according to Eric Jonasch, MD.
The precise cause of kidney cancer is unknown, however the two main causes of kidney failure are diabetes and high blood pressure, which are responsible for more than 70 percent of all kidney failure cases. Therefore, kidney failure and disease can often be delayed or prevented...
Natural products possess enormous structural and chemical diversity and are a rich source of drugs or drug-like leads. Although the final products may not necessarily represent the active ingredients of the natural source, the majority of all drugs in the market have their origin in nature. Englerin A is guaiane sesquiterpene that was isolated from the Tanzanian plant Phyllanthus engleri and has attracted much attention because of its unique structure and cytotoxicity profile in cancer cells.
Argos Therapeutics Inc said on Wednesday that an independent data monitoring committee concluded that the company's experimental treatment for metastatic renal cell carcinoma would likely fail.
|Powered by NeonCRM|